Johnson & Johnson (JNJ) 64.77 0.16

Johnson & Johnson
(JNJ) 64.77 0.16

Last Trade:	64.76	Day Range:	64.63 - 64.95
Trade Time:	11:02AM	52wk Range:	57.50 - 68.05
Prev. Close:	64.60	Market Cap:	176.85B
Open:	64.90	Div Yield:	3.47
Volume:	2443976	PE:	190
EPS:	3.49

The Latest On JNJ

S&P Futures & Big 10 Analysis - Week of February 13 2/13/12 11:13am

Grandpa's 2012 ETF Portfolio 2/10/12 1:48pm

S&P Futures & Big 10 Analysis - Week of Feb 6, 2012 2/6/12 11:19am

Benzinga's M&A Chatter for Thursday February 2, 2012 2/2/12 7:57pm

UPDATE: First Global Downgrades Johnson & Johnson to Market Perform 2/2/12 10:02am

First Global Downgrades Johnson & Johnson to Market Perform 2/2/12 9:21am

S&P Futures & Big 10 Analysis - Week of Jan 30th, 2012 1/31/12 4:10pm

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12 6:24pm

Piper Jaffray Lowers PT on Johnson & Johnson to $68 1/25/12 8:34am

Morgan Stanley Concerned with Johnson & Johnson Sustaining a Path to Leverage 1/25/12 8:10am

Morgan Keegan Maintains Market Perform Rating on Johnson & Johnson 1/25/12 8:01am

S&P Futures & Big 10 Analysis - Week of February 13 2/13/12

Grandpa's 2012 ETF Portfolio 2/10/12

S&P Futures & Big 10 Analysis - Week of Feb 6, 2012 2/6/12

Benzinga's M&A Chatter for Thursday February 2, 2012 2/2/12

UPDATE: First Global Downgrades Johnson & Johnson to Market Perform 2/2/12

First Global Downgrades Johnson & Johnson to Market Perform 2/2/12

S&P Futures & Big 10 Analysis - Week of Jan 30th, 2012 1/31/12

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12

Piper Jaffray Lowers PT on Johnson & Johnson to $68 1/25/12

Morgan Stanley Concerned with Johnson & Johnson Sustaining a Path to Leverage 1/25/12

Morgan Keegan Maintains Market Perform Rating on Johnson & Johnson 1/25/12

S&P Futures & Big 10 Analysis - Week of February 13 2/13/12

Grandpa's 2012 ETF Portfolio 2/10/12

S&P Futures & Big 10 Analysis - Week of Feb 6, 2012 2/6/12

Benzinga's M&A Chatter for Thursday February 2, 2012 2/2/12

S&P Futures & Big 10 Analysis - Week of Jan 30th, 2012 1/31/12

Benzinga's M&A Chatter for Thursday January 26, 2012 1/26/12

Benzinga's M&A Chatter for Tuesday January 24, 2012 1/24/12

Stocks To Watch For January 24 1/24/12

Johnson & Johnson Earnings Preview 1/24/12

Earnings Expectations for the Week of January 23 1/22/12

Benzinga's M&A Chatter for Wednesday January 18, 2012 1/18/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

UPDATE: First Global Downgrades Johnson & Johnson to Market Perform 2/2/12

First Global Downgrades Johnson & Johnson to Market Perform 2/2/12

Piper Jaffray Lowers PT on Johnson & Johnson to $68 1/25/12

Morgan Stanley Concerned with Johnson & Johnson Sustaining a Path to Leverage 1/25/12

Morgan Keegan Maintains Market Perform Rating on Johnson & Johnson 1/25/12

JP Morgan Reiterates Neutral on Johnson & Johnson 1/24/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Are the Samsung M&A Rumors True? 12/1/11

Piper Jaffray Maintains Neutral Rating and $69 PT on Johnson & Johnson 12/1/11

UPDATE: Citi Lowers PT to $70 on Johnson & Johnson 11/29/11

Citigroup Lowers PT on Johnson & Johnson to $70 11/29/11

Trade JNJ
NOW!

Partner Headlines

Gilead, Vertex and the Mystery of Missing Hep C Patients 2/13/12

10 Companies in the 'Ultimate Stock Pickers' Portfolio 2/13/12

Betting On Biotech 2/10/12

Watson Settles Patent Dispute - Analyst Blog 2/10/12

Abbott Labs Offers Long, Solid Dividend History 2/10/12

The 10 Must-Know Market Forces for 2012 2/10/12

Johnson & Johnson (JNJ) - A Reliable Dividend Growth Stock 2/10/12

Healthy Health Care ETF? 2/9/12

Tweedy Browne Q4 Portfolio: Buys JNJ, EMR, SYY, COP, LMT, MMM 2/9/12

4 IPOs to Watch...and None are Facebook 2/9/12

Ten Big Pharma Stocks' Juicy Dividend Payouts, With Cash-on-Hand as Cushion 2/8/12

Cardica's Losses Trim in 2Q - Analyst Blog 2/8/12

Press Releases

Johnson & Johnson to Participate in 2012 Leerink Swann Global Health Care Conference 2/9/12 Newswire Story

Davis Names Top-25 Companies with Most Brand Capital in 2011 2/6/12 Business Wire Story

La Jolla Pharmaceutical Company Acquires GCS-100, a First-in-Class Galectin-3 Antagonist 1/20/12 Business Wire Story

Fish & Richardson Attorneys Tom Melsheimer, Tommy Jacks Help Whistleblower, State of Texas Earn Historic Settlement in Lawsuit Over Risperdal Medication 1/19/12 Newswire Story

Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2011 Financial Results 1/17/12 Newswire Story

Johnson & Johnson Announces First-Quarter 2012 Quarterly Dividend 1/3/12 Newswire Story

Research and Markets: Large Cap Value and Other Investing Strategies Report 12/22/11 Business Wire Story

Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 12/8/11 Newswire Story

Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc. 12/8/11 Newswire Story

Johnson & Johnson to Participate in the Piper Jaffray 23rd Annual Health Care Conference 11/28/11 Newswire Story

Johnson & Johnson to Participate in the Piper Jaffray 23rd Annual Health Care Conference 11/22/11 Newswire Story

Research and Markets: Investing Strategies Report 2011 11/18/11 Business Wire Story

Get the latest JNJ stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Johnson & Johnson stock price.

Johnson & Johnson by YCharts

Johnson & Johnson (JNJ) 64.77 0.16

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On JNJ

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social